Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Trial Profile

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Busulfan; Dexamethasone; Enoxaparin sodium; Gemcitabine; Glutamine; Melphalan; Palifermin; Pyridoxine; Rituximab; Vorinostat
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Jun 2021.
    • 22 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 28 Apr 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top